Q-omics provides the consensus-scored ZNF30 profile across patient tissues and cancer cell-line models. ZNF30 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF30 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ZNF30 RNA expression shows 20,598 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, LIHC, and UVM as cancer lineages where ZNF30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF30 survival associations across molecular data types. ZNF30 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF30 RNA expression–survival associations across cancer types. High ZNF30 expression shows unfavorable associations in LGG, LIHC and ACC, but favorable associations in BRCA, READ and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF30 RNA expression.
This table summarizes ZNF30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF30 shows lower tumor expression in KICH and higher tumor expression in LIHC, COAD, STAD, BRCA and CHOL. The LIHC box plot shows higher ZNF30 RNA expression in tumor versus normal tissue (log2 FC = +0.998, t-test p < 0.001).
This table shows molecular features associated with ZNF30 in patient tissues and cancer cell lines. In patient samples, ZNF30 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
